Investigational drug · Phase 3
ATYR1923
Also called: KRP-R120, Efzofitimod
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Interstitial Lung Disease, Pulmonary Sarcoidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "ATYR1923"
First trial start
2022
Sep 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATYR1923", any sponsor or status.
Conditions studied
As listed on its trial records.
- Interstitial Lung Disease
- Pulmonary Sarcoidosis
Largest trials
Live from ClinicalTrials.gov: studies naming "ATYR1923" as an intervention, largest first.
- Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisPivotal-lookingCompleted
aTyr Pharma, Inc.Industry
NCT05415137 · 268 participants · Start Sep 15, 2022 · Primary completion Jun 25, 2025
Drug: Efzofitimod 3 mg/kg; Efzofitimod 5 mg/kg and 1 more · For: Pulmonary Sarcoidosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 91 sites in all
aTyr Pharma, Inc.Industry
NCT03824392 · 37 participants · Start Jan 29, 2019 · Primary completion Jun 29, 2021
Drug: Efzofitimod 1.0 mg/kg or Placebo; Efzofitimod 3.0 mg/kg or Placebo and 1 more · For: Pulmonary Sarcoidosis
Sites: Birmingham, Alabama; Northridge, California; Denver, Colorado · 15 sites in all
aTyr Pharma, Inc.Industry
NCT04412668 · 36 participants · Start Jun 4, 2020 · Primary completion Oct 23, 2020
Drug: Efzofitimod 1 mg/kg; Efzofitimod 3 mg/kg and 1 more · For: SARS-CoV-2 (COVID-19) Severe Pneumonia
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Miami, Florida · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Macrophage Polarization in Sarcoidosis: Implications for Granuloma Formation, Fibrosis, and Therapeutic Strategies.
Shamaei M · Thorac Res Pract 2026
- Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Culver DA, Bonella F, Gupta R, et al. · Lancet Respir Med 2026
- New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.
Drakopanagiotakis F, Papanikolaou I, Panou T, et al. · Int J Mol Sci 2026
- Multidisciplinary strategies and new technologies in the management of sarcoidosis.
Tana C, Drent M, Obi ON, et al. · Eur J Intern Med 2026
- Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.
Bechman K, Biddle K, Miracle A, et al. · Thorax 2025
- New therapeutic options in sarcoidosis.
Nunes H, Hindré R, Jeny F · Curr Opin Pulm Med 2025
Also in development for Interstitial Lung Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.